ArticleJournal of ovarian research2025
Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis.
Kun Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.